One backbone, three receptors
Retatrutide, developed under the code LY3437943, was engineered to act at the GLP-1, GIP and glucagon receptors from a single peptide chain. Getting balanced activity at three targets out of one sequence is a considerable piece of protein engineering.
The glucagon arm is what sets it apart from the dual agonists. Glucagon receptor activity is associated with energy expenditure rather than intake, which in principle adds a route the GLP-1 and GIP arms do not cover.
Building glucagon activity into a metabolic compound looks backwards at first glance, because glucagon raises blood glucose. The reasoning is that the incretin arm, the one the pathway page takes apart in detail, pulls in the opposite direction on that variable, which leaves the glucagon receptor free to contribute on the expenditure side instead.
What phase 2 did and did not show
The published phase 2 work reported weight reductions at 48 weeks larger than anything previously seen in the class. That result is real, peer-reviewed and worth taking seriously.
It is also phase 2: several hundred participants, under a year, with efficacy as the primary question. Phase 3 is where rarer effects surface and where results either hold or shrink. Anyone telling you the story is settled is ahead of the data.
Readers who search for what is retatrutide usually meet a single figure repeated across a hundred summaries. A registry is the better starting point, because the entries on ClinicalTrials.gov record which studies are running, what each is measuring and how far the programme has actually travelled, none of which survives into a headline.
| Development code | LY3437943 |
| Class | Triple receptor agonist |
| Receptors | GLP-1, GIP, glucagon |
| Distinguishing arm | Glucagon receptor |
| Format | Research vial, 30 mg |
| Purity | ≥ 99% (HPLC) |
| Evidence base | Published phase 2 results |
| Category | Research use only |
Every row describes the substance. None describes a person.
Why demand outran approval
Interest in retatrutide arrived long before any regulatory decision, largely on the strength of one set of published figures circulating widely. That gap between attention and evidence is where unreliable supply tends to appear.
It is also why the certificate matters more here than almost anywhere else in the catalogue. High demand and no approved product is precisely the combination that attracts misrepresented material.
Two things follow. Identity, not purity, is the first question to put to a batch: a document can report an impressive figure for whatever sits in the vial without that material being what the label claims. And how a supplier behaves around documentation tells you more than the document does, which is the subject of our list of supplier warning signs.
Reading retatrutide against the finished programmes
The useful comparison is not with the other unapproved compounds but with the two molecules in this class that have completed programmes. The tirzepatide page covers a dual agonist with a finished phase 3 record; semaglutide carries more published work behind it than anything else on this site. Set retatrutide beside either and the difference is not in the reported effect size. It is in how much has been ruled out.
That distinction is easy to lose, because effect sizes are the part that travels. Durability past a year, uncommon adverse findings and behaviour in groups a mid-stage trial never enrolled are all invisible in the number everyone quotes, and every one of them is something a later programme exists to surface. Watching the indexed publications on PubMed accumulate over time is the least filtered way to see whether they do.
Retatrutide in the catalogue
A 99% purity floor, verified per lot before anything leaves the laboratory.
Where Retatrutide fits in
Where this article leads next.
Retatrutide side effects
What the trial data reported, separated from what forums report.
Read ComparisonRetatrutide vs tirzepatide vs semaglutide
Three compounds, three evidence bases, side by side.
Read QualityHow to spot a fake COA
The document that matters most when demand outstrips legitimate supply.
ReadAbout Retatrutide
What people ask us about this one.